Cardiac [ 99m Tc]Tc-hydroxydiphosphonate uptake on bone scintigraphy in patients with hereditary transthyretin amyloidosis: an early follow-up marker?

Autor: Tingen HSA; Department of Nuclear Medicine and Molecular Imaging, University Medical Centre Groningen and Amyloidosis Centre of Expertise, Groningen, The Netherlands. h.s.a.tingen@umcg.nl., Tubben A; Department of Cardiology, University Medical Centre Groningen and Amyloidosis Centre of Expertise, Groningen, The Netherlands., Bijzet J; Department of Rheumatology & Clinical Immunology, University Medical Centre Groningen and Amyloidosis Centre of Expertise, Groningen, The Netherlands., van den Berg MP; Department of Cardiology, University Medical Centre Groningen and Amyloidosis Centre of Expertise, Groningen, The Netherlands., van der Meer P; Department of Cardiology, University Medical Centre Groningen and Amyloidosis Centre of Expertise, Groningen, The Netherlands., Houwerzijl EJ; Department of Internal Medicine, University Medical Centre Groningen and Amyloidosis Centre of Expertise, Groningen, The Netherlands., Muntinghe FLH; Department of Internal Medicine, University Medical Centre Groningen and Amyloidosis Centre of Expertise, Groningen, The Netherlands., van der Zwaag PA; Department of Clinical Genetics, University Medical Centre Groningen and Amyloidosis Centre of Expertise, Groningen, The Netherlands., Glaudemans AWJM; Department of Nuclear Medicine and Molecular Imaging, University Medical Centre Groningen and Amyloidosis Centre of Expertise, Groningen, The Netherlands., Oerlemans MIFJ; Department of Cardiology and Member of the European Reference Network for rare, low prevalence and complex diseases of the heart: ERN GUARD-Heart , University Medical Centre Utrecht, Utrecht, The Netherlands., Knackstedt C; Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre +, Maastricht, The Netherlands., Michels M; Department of Cardiology, University Medical Centre Rotterdam, Rotterdam, The Netherlands., Hirsch A; Department of Radiology and Nuclear Medicine, University Medical Centre Rotterdam, Rotterdam, The Netherlands., Hazenberg BPC; Department of Rheumatology & Clinical Immunology, University Medical Centre Groningen and Amyloidosis Centre of Expertise, Groningen, The Netherlands., Slart RHJA; Department of Nuclear Medicine and Molecular Imaging, University Medical Centre Groningen and Amyloidosis Centre of Expertise, Groningen, The Netherlands.; Biomedical Photonic Imaging Group, Faculty of Science and Technology, University of Twente, Enschede, The Netherlands., Nienhuis HLA; Department of Internal Medicine, University Medical Centre Groningen and Amyloidosis Centre of Expertise, Groningen, The Netherlands.
Jazyk: angličtina
Zdroj: European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2024 Feb; Vol. 51 (3), pp. 681-690. Date of Electronic Publication: 2023 Oct 16.
DOI: 10.1007/s00259-023-06459-y
Abstrakt: Purpose: There is a need for early quantitative markers of potential treatment response in patients with hereditary transthyretin (ATTRv) amyloidosis to guide therapy. This study aims to evaluate changes in cardiac tracer uptake on bone scintigraphy in ATTRv amyloidosis patients on different treatments.
Methods: In this retrospective cohort study, outcomes of 20 patients treated with the transthyretin (TTR) gene silencer patisiran were compared to 12 patients treated with a TTR-stabilizer. Changes in NYHA class, cardiac biomarkers in serum, wall thickness, and diastolic parameters on echocardiography and NYHA class during treatment were evaluated.
Results: Median heart/whole-body (H/WB) ratio on bone scintigraphy decreased from 4.84 [4.00 to 5.31] to 4.16 [3.66 to 4.81] (p < .001) in patients treated with patisiran for 29 [15-34] months. No changes in the other follow-up parameters were observed. In patients treated with a TTR-stabilizer for 24 [20 to 30] months, H/WB ratio increased from 4.46 [3.24 to 5.13] to 4.96 [ 3.39 to 5.80] (p = .010), and troponin T increased from 19.5 [9.3 to 34.0] ng/L to 20.0 [11.8 to 47.8] ng/L (p = .025). All other parameters did not change during treatment with a TTR-stabilizer.
Conclusion: A change in cardiac tracer uptake on bone scintigraphy may be an early marker of treatment-specific response or disease progression in ATTRv amyloidosis patients.
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje